These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36540927)

  • 41. Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis.
    Nakai T; Fukui S; Ikeda Y; Shimizu H; Tamaki H; Okada M
    Clin Rheumatol; 2020 Dec; 39(12):3653-3659. PubMed ID: 32577850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
    Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of belimumab therapy in systemic lupus erythematosus: A systematic review and meta-analysis.
    Chiang HY; Guo ZA; Wu TW; Peng TR
    Lupus; 2022 May; 31(6):666-673. PubMed ID: 35321609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review.
    Elshaer R; Jaber S; Odeh N; Arbili L; Al-Mayouf SM
    Clin Rheumatol; 2024 Mar; 43(3):863-877. PubMed ID: 38079010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.
    Shipa M; Embleton-Thirsk A; Parvaz M; Santos LR; Muller P; Chowdhury K; Isenberg DA; Doré CJ; Gordon C; Ehrenstein MR;
    Ann Intern Med; 2021 Dec; 174(12):1647-1657. PubMed ID: 34698499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus.
    Cheng H; Zhang XY; Yang HD; Yu Z; Yan CL; Gao C; Wen HY
    Front Immunol; 2022; 13():911730. PubMed ID: 35979351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus.
    Wu C; Gong B
    Immun Inflamm Dis; 2022 Nov; 10(11):e716. PubMed ID: 36301032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
    Zhang F; Zheng J; Li Y; Wang G; Wang M; Su Y; Gu J; Li X; Bass D; Chu M; Curtis P; DeRose K; Kurrasch R; Lowe J; Meizlik P; Roth DA
    RMD Open; 2022 Apr; 8(1):. PubMed ID: 35428697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
    Sohrabian A; Parodis I; Carlströmer-Berthén N; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I; Rönnelid J
    Arthritis Res Ther; 2019 Nov; 21(1):259. PubMed ID: 31783909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
    Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
    BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
    Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
    Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study.
    Zhang S; Qiu Q; Zeng S; Li H; Xu L; Jie L; Hu X; Xiao Y; Chen D; Zhan Z; Liang L; Yu Q; Xu H
    Clin Rheumatol; 2024 Jan; 43(1):199-208. PubMed ID: 37982925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
    Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.